An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)

Forma Therapeutics Inc.0 sites344 target enrollmentFebruary 11, 2022

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Forma Therapeutics Inc.
Enrollment: 344
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

February 11, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Forma Therapeutics Inc.

Eligibility Criteria

Inclusion Criteria

•1\. Patient has provided documented informed consent or assent (the informed consent form \[ICF] must be reviewed and signed by each patient; in the case of adolescent patients, both the consent of the patient’s legal representative or legal guardian, and the patient’s assent must be obtained)
•3\. Patient has a confirmed diagnosis of sickle cell disease
•Documentation of SCD genotype (HbSS, HbSß0\-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing; if unavailable, must be confirmed by laboratory testing during screening
•4\. Patient has had at least 2 episodes of VOC in the past 12 months
•For study eligibility, VOC is defined as a previously documented episode of ACS or acute painful crisis (for which there was no explanation other than VOC) which required prescription or healthcare professional\-instructed use of analgesics for moderate to severe pain (documentation must exist in the patient medical record prior to Screening)
•5\. Hemoglobin \= 5\.5 and \= 10 g/dL (\= 55 and \= 100 g/L) during screening
•6\. For participants taking HU, the dose of HU (mg/kg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the Investigator
•7\. Patients, who if female and of child bearing potential, are using highly effective methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.

Exclusion Criteria

•1\. More than 10 VOCs (as defined in Inclusion Criterion 4\) within the past 12 months
•2\. Hospitalized for sickle cell crisis or other vaso\-occlusive event within 14 days of signing the ICF
•3\. Female who is breast feeding or pregnant
•4\. Hepatic dysfunction characterized by:
•Alanine aminotransferase (ALT) \> 4\.0 × upper limit of normal (ULN)
•Direct bilirubin \> 3\.0 × ULN
•5\. Patients with clinically significant bacterial, fungal, parasitic, or viral infection requiring systemic therapy
•Patients with acute bacterial, fungal, parasitic, or viral infection requiring systemic therapy should delay screening/enrollment until active therapy has been completed
•Note: Infection prophylaxis is allowed (see concomitant medication restrictions)
•6\. Known human immunodeficiency virus (HIV) positivity